US biotechnology company Terremoto Biosciences has appointed Charles Baum CEO. He succeeds Peter Thompson, who will continue to serve as Terremoto’s board chairperson.

Bristol-Myers Squibb (BMS) announced that it will acquire Mirati Therapeutics for up to $5.8 billion. BMS is to pay $58.00 per share in cash, for a total equity value of...